Data Sheet (Cat.No.T78212)

TargetMol

Zoldonrasib

Chemical Properties



CAS No. : 2922732-54-3

Formula: C63H88F3N11O7

Molecular Weight: 1168.44

Storage: Keep away from moisture,Store at low temperature,
Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Zoldonrasib (RMC-9805) is a mutant-selective covalent KRAS G12D inhibitor with oral activity and significant antitumor activity, inducing tumor cell apoptosis in preclinical models of various KRAS-mutant cancers.
Targets(IC50)	Apoptosis,Ras,Kras
In vitro	**METHODS**:eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells were treated with Zoldonrasib (100 nM) for 48 h; cytokine levels were measured by cytokine array, and cell surface expression was detected by flow cytometry. **RESULTS**: CXCL1 and GM-CSF were decreased, PD-L1 and PVR were decreased; CXCL10 and CCL17 were increased, MHC-I and MHC-II were increased in eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells. [2]
In vivo	**METHODS: To detect in vivo anti-tumor activity, Zoldonrasib (100 mg/kg) was orally administered to eCT26 (KRASG12D/G12D) xenograft tumor mice once a day for 4-8 days.** **RESULTS: Zoldonrasib exhibits anti-tumor activity in the KRAS G12D xenograft model. [2]**

Solubility Information

Solubility	DMSO: 252.5 mg/mL (216.1 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (4.28 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.8558 mL	4.2792 mL	8.5584 mL
5 mM	0.1712 mL	0.8558 mL	1.7117 mL
10 mM	0.0856 mL	0.4279 mL	0.8558 mL
50 mM	0.0171 mL	0.0856 mL	0.1712 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Weller C, et al. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science. 2025 Jul 24;389(6758):eads0239.

Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement): 3475